Business Context and Reporting Period
This Form 8-K Current Report was filed by NanoVibronix, Inc. (not Envue Medical, Inc.) on June 26, 2019, covering events occurring on June 20 and June 21, 2019. The company is a Delaware corporation listed on the Nasdaq Capital Market and is classified as an emerging growth company. The filing primarily details the closing of a private placement financing and the results of the 2019 Annual Meeting of Stockholders.
Key Financial Metrics and Capital Structure
- Financing Proceeds: The company raised aggregate gross proceeds of $3,200,000 through a private placement.
- Securities Issued:
- 1,600,000 shares of Series E Convertible Preferred Stock.
- Warrants to purchase 1,600,000 shares of Series E Preferred Stock at an exercise price of $2.50 per share.
- Purchase Price: $2.00 per unit (one share of Series E Preferred Stock plus one warrant).
- Conversion Terms: Each share of Series E Preferred Stock is convertible into one share of Common Stock, subject to a 9.99% beneficial ownership limitation and stockholder approval.
- Liquidity and Debt: The filing does not provide specific data on operating cash flow, total debt, or current liquidity ratios beyond the new capital raised.
Material Changes and Corporate Actions
- Capital Raise: Entry into a Material Definitive Agreement for the sale of Series E Preferred Stock and Warrants to existing stockholders.
- Equity Plan Amendment: Stockholders approved an amendment to the 2014 Long-Term Incentive Plan, increasing the share reserve by 400,000 shares to a total of 1,864,286 shares.
- Board Elections: Six directors were elected to the Board of Directors for a one-year term: Brian Murphy, Christopher Fashek, Martin Goldstein, Harold Jacob, Michael Ferguson, and Thomas R. Mika.
- Accounting Firm Ratification: Marcum LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2019.
Outlook, Risks, and Contingencies
- Stockholder Approval Requirement: The company must obtain stockholder approval for the issuance of Common Stock upon conversion of the Series E Preferred Stock. A special meeting must be held within 90 days of the financing closing.
- Registration Statement Obligations: The company must file a registration statement for the resale of underlying shares within 60 days of stockholder approval and have it declared effective within 120 to 150 days.
- Liquidated Damages: If the registration statement is not filed or declared effective within the specified timelines, the company must pay investors 1.0% of the purchase price per month as liquidated damages, capped at 5% of the aggregate purchase price.
- Conversion Restrictions: Conversion is restricted if it would cause a holder to beneficially own more than 9.99% of the outstanding Common Stock, unless waived with 61 days' prior notice after stockholder approval.
Investor Verification Checklist
- Verify the exact date and outcome of the special stockholder meeting required to approve the conversion of Series E Preferred Stock.
- Confirm the filing status and effectiveness date of the registration statement covering the resale of the underlying Common Stock.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) and Certificate of Designation (Exhibit 4.1) for additional covenants or restrictions.
- Monitor the company's compliance with the 90-day deadline to call the special stockholder meeting.
- Check for any subsequent filings regarding the exercise of the warrants issued in this financing.